Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS

In its upcoming report, Zimmer Biomet (ZBH) is predicted by Wall Street analysts to post quarterly earnings of $1.98 per share, reflecting a decline of 1.5% compared to the same period last year. Revenues are forecasted to be $2.04 billion, representing a year-over-year increase of 5.3%.The current level reflects an upward revision of 0.4% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.In light of this perspective, let's dive into the average estimates of certain Zimmer metrics that are commonly tracked and forecasted by Wall Street analysts.Analysts expect 'Net Sales- Knees' to come in at $823.52 million. The estimate suggests a change of +2.8% year over year.The average prediction of analysts places 'Net Sales- S.E.T' at $536.91 million. The estimate suggests a change of +14.4% year over year.It is projected by analysts that the 'Net Sales- Hips' will reach $522.85 million. The estimate points to a change of +3.2% from the year-ago quarter.Based on the collective assessment of analysts, 'Net Sales- Knees- International' should arrive at $376.44 million. The estimate indicates a year-over-year change of +4.6%.According to the collective judgment of analysts, 'Net Sales- Hips- International' should come in at $256.18 million. The estimate indicates a change of +3.5% from the prior-year quarter.The collective assessment of analysts points to an estimated 'Net Sales- Knees- United States' of $451.86 million. The estimate indicates a year-over-year change of +2.4%.The consensus estimate for 'Net Sales- Hips- United States' stands at $267.81 million. The estimate points to a change of +3.4% from the year-ago quarter.Analysts' assessment points toward 'Net Sales- United States' reaching $1.17 billion. The estimate suggests a change of +6.2% year over year.The consensus among analysts is that 'Net Sales- International' will reach $872.89 million. The estimate points to a change of +4.4% from the year-ago quarter. View all Key Company Metrics for Zimmer here>>> Over the past month, Zimmer shares have recorded returns of -0.2% versus the Zacks S&P 500 composite's +1% change. Based on its Zacks Rank #4 (Sell), ZBH will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Zimmer Biomet Holdings, Inc. (ZBH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks